Novel CAR T that targets MUC1* not full-length MUC1 for treatment of solid tumor cancers

      We developed a CAR T therapeutic to treat solid tumors. Over 75% of solid tumors aberrantly express the transmembrane glycoprotein MUC1. More accurately, these tumors express the cleavage product, MUC1*, which we showed is the growth factor receptor form. The targeting head of our CAR T is a humanized antibody that binds an epitope on MUC1* that is not exposed on full-length MUC1. Expression of MUC1*, but not full-length MUC1, increases as tumor stage increases and also as cancers acquire drug resistance. All previous therapies that targeted full-length MUC1 have failed, presumably because as cancers progress, cleavage of MUC1 extra cellular domain increases and the targeted portion is shed from the cell surface. More recent CAR T therapeutics, such as those using 5E5, target aberrant O-linked glycans, which only exist on full-length MUC1. This approach would only enrich for the tumor-promoting MUC1* form.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect